Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post Marketing Surveillance Study to Monitor the Risk of Urinary Retention in Retigabine Users

NCT01462656 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01462656
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01462656 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post Marketing Surveillance Study to Monitor the Risk of Urinary Retention in Retigabine Users
Lead sponsor
GlaxoSmithKline
Phase
Observational
Overall status
Terminated
Start date
February 28, 2011
Completion date
August 31, 2016
Enrollment
1 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy